# Lebrikizumab in Moderate-to-severe Atopic Dermatitis

> **NCT06906497** · PHASE4 · RECRUITING · sponsor: **Johann E Gudjonsson MD PhD** · enrollment: 48 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** lebrikizumab

## Key facts

- **NCT ID:** NCT06906497
- **Lead sponsor:** Johann E Gudjonsson MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906497, "Lebrikizumab in Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06906497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*